^
    23h
    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant (clinicaltrials.gov)
    P2, N=3, Terminated, Emory University | N=19 --> 3 | Trial completion date: Nov 2026 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> May 2025; Slow Accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Lenvima (lenvatinib)
    1d
    Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Washington University School of Medicine | Trial completion date: Aug 2026 --> Oct 2027 | Trial primary completion date: Aug 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    dasatinib
    1d
    Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    1d
    Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. (PubMed, Nat Biotechnol)
    We experimentally validated several actionable findings, including tepotinib to target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway in pancreatic cancer and gilteritinib to overcome MET mutation-driven drug resistance and metastasis. To facilitate exploration of our data, we provide KIRHub, a web-based tool that allows identification of existing inhibitors of wild-type and mutated kinases to guide precision oncology.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • MARK2 (Microtubule Affinity Regulating Kinase 2)
    |
    MET mutation
    |
    Xospata (gilteritinib) • Alunbrig (brigatinib) • Tepmetko (tepotinib)
    1d
    Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case. (PubMed, Cureus)
    The patient was managed by transurethral resection of bladder tumor (TURBT) followed by targeted therapy with sunitinib (37.5 mg)...ccRCC can metastasize to unusual sites, including the urinary bladder. Early recognition through comprehensive imaging and immunohistochemical evaluation is essential for timely diagnosis and management.
    Journal
    |
    CA9 (Carbonic anhydrase 9) • MME (Membrane Metalloendopeptidase) • PAX8 (Paired box 8)
    |
    sunitinib
    1d
    C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
    Our study identified C/EBP-β as a key effector of the terminal pro-apoptotic ER stress response. While the direct clinical application of TM is limited by its systemic toxicity, these findings highlight the clinical translational potential of targeting the ER stress-C/EBP-β axis, offering a novel combination therapeutic strategy for patients with acquired sorafenib resistance.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    sorafenib
    1d
    Identification of Drug-resistant Cell Subpopulations in Colorectal Cancer Through Single-cell Analysis and Exploration of Potential Therapeutic Strategies. (PubMed, Curr Med Chem)
    This study provided potential therapeutic possibilities for oxaliplatin resistance, contributing to CRC treatment.
    Journal
    |
    IL17A (Interleukin 17A) • PPIA (Peptidylprolyl Isomerase A)
    |
    dasatinib • oxaliplatin
    2d
    Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Emory University | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    2d
    RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. (clinicaltrials.gov)
    P3, N=442, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • gemcitabine • Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)
    3d
    Discovery of novel CSF1R inhibitor for triple-negative breast cancer (TNBC) treatment through TAMs reprogramming. (PubMed, Biochem Pharmacol)
    More importantly, LL-08 caused less damage to the liver than pexidartinib, which was in accordance with its enzymatic and cellular selectivity. In summary, LL-08 is a highly active and selective CSF1R inhibitor, showing potential for TNBC treatment by TAMs reprogramming.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL10 (Interleukin 10)
    |
    Turalio (pexidartinib)
    4d
    Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. (PubMed, Clin Cancer Res)
    These findings highlight genomic context in shaping BH3 mimetic responses and point to rational combination of this class of drugs with anti-leukemic agents such as asparaginase.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
    |
    dasatinib • AZD4320